Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2019-10-25 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
2019年第三季度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (370 characters) stating that the company's 2019 third quarter report will be published on a specific date and website. It does not contain the actual financial data or report itself, but merely informs investors about the upcoming release. According to the 'MENU VS MEAL' rule, such a brief notice about report publication is classified as a Report Publication Announcement (RPA).
2019-10-25 Chinese
关于子公司使用暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 福安药业（集团）股份有限公司 regarding the use of temporarily idle raised funds by its subsidiary for cash management. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, details the amount and purpose of the cash management, and includes approvals from the board, supervisory committee, and independent financial advisors. The document does not contain financial statements or detailed financial results but is a formal disclosure about the company's fundraising capital usage and management plans. It fits the category of Capital/Financing Update (CAP) as it updates on the use and management of raised funds, specifically cash management of idle raised capital.
2019-10-25 Chinese
东莞证券股份有限公司关于公司子公司使用暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion regarding the use of temporarily idle raised funds by a subsidiary of the company for cash management. It references regulatory requirements related to the management and use of raised funds, details the approval process by the board and supervisory committee, and confirms compliance with relevant laws and stock exchange rules. The document is not a full annual or interim financial report, nor is it an earnings release or a simple announcement. It is a specialized report focused on the audit and verification of the use of raised funds, which aligns with the category of Audit Report / Information (AR). The document length (5418 characters) and content indicate it is the report itself, not just an announcement of a report. Therefore, the appropriate classification is AR with high confidence. FY 2019
2019-10-25 Chinese
第四届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 福安药业 (Fuan Pharmaceutical Group Co., Ltd.) dated October 25, 2019. It details the approval of the 2019 third quarter report and other board decisions. The text includes voting results and mentions the meeting was held according to company law and articles of association. The document does not contain the full quarterly report itself but announces the board's approval of it and references where the full report is published. The document length is short (842 characters), and it serves as an official announcement of board resolutions rather than the report itself. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting decisions and resolutions.
2019-10-25 Chinese
第四届监事会第七次会议决议公告
Board/Management Information Classification · 85% confidence The document is a resolution announcement from the Supervisory Board of the company 福安药业 (Fuan Pharmaceutical Group) regarding the review and approval of the company's 2019 third quarter report. It includes the Supervisory Board's written audit opinion on the quarterly report, confirming its compliance with regulations and accuracy. The document also mentions approval of a cash management plan for temporarily idle raised funds. The document is relatively short (932 characters) and primarily serves as an announcement of the Supervisory Board's review and approval of the quarterly report, rather than containing the full quarterly report itself. Therefore, it is not the quarterly report (IR) itself but an announcement related to governance and supervisory board decisions. It does not fit the categories of full financial reports or earnings releases, nor is it a regulatory filing or management report. The best fitting category is Board/Management Information (MANG) as it announces decisions and approvals by the Supervisory Board, which is part of company management oversight.
2019-10-25 Chinese
关于股东股份减持计划实施进展情况的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the progress of a shareholder's share reduction plan. It details the number of shares reduced, the methods of reduction, dates, and compliance with relevant securities laws and regulations. It does not contain financial statements or comprehensive financial data but focuses on shareholding changes by significant shareholders. This fits the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels. The document length is 2213 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is MRQ.
2019-10-23 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.